Apr 30 - Private: ABO Pharmaceuticals to Offer PharmaJet Needle-Free Injection System
GOLDEN, Colo. - May 28, 2015 - Today, PharmaJet, the maker of innovative, needle-free injector technology, announced a partnership with ABO Pharmaceuticals, a leader in the flu vaccine distribution market and a worldwide distributor of biological and pharmaceutical products. Through this arrangement, ABO Pharmaceuticals will offer the PharmaJet Needle-Free Injection System for needle-free flu shots1 throughout the United States. The product is currently available for pre-book for the 2015/16 flu season.
ABO Pharmaceuticals’ specialty flu vaccine and product distribution program, referred to as “Got Flu,” aims to offer the fastest, most convenient and most affordable products.
“Entering the market this year, the PharmaJet Needle-Free Injector has been well received by patients and health care providers alike. In fact, 93 percent of patients and 87 percent of health care providers reported that they would choose the Pharmajet needle-free option again for the upcoming flu season,” said Ron Lowy, PharmaJet chairman and CEO. “We are excited to partner with ABO to assist in our nationwide roll out of PharmaJet Needle-Free Flu Shots, and we anticipate that the increased availability of the device will enable greater vaccination compliance in the U.S.”
1. Refer to Instructions for Use and the individual device & drug/biologic labeling for prescribing information to ensure safe injections and to review risks.
About PharmaJet, Inc.
Based in Golden, Colorado, PharmaJet was founded with the goal of reducing the use of medical needles throughout the world. PharmaJet’s innovative Stratis® Injector has U.S. FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. In August 2014, the PharmaJet Needle-Free Injector was approved for delivery of an influenza vaccine to deliver needle-free flu shots. The PharmaJet Needle-Free Injector is easy-to-use and eliminates needlestick injuries, needle reuse and cross contamination, and helps reduce sharps waste disposal. For more information, visit www.PharmaJet.com.
Mar 27 - Recommended composition of influenza virus vaccines for use in the 2015-2016 northern hemisphere influenza season
It is recommended that trivalent vaccines for use in the 2015-2016 influenza season (northern hemisphere winter) contain the following:
- an A/California/7/2009 (H1N1)pdm09-like virus;
- an A/Switzerland/9715293/2013 (H3N2)-like virus;
- a B/Phuket/3073/2013-like virus.
It is recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and a B/Brisbane/60/2008-like virus.
ABO Pharmaceuticals is now accepting orders for the 2015-2016 Influenza Season. Please contact your Got Flu? Rep for pre-booking specials and get priority ship dates!
1.) "WHO: Influenza"; http://www.who.int
Feb 10 - ABO Pharmaceuticals is proud to introduce PharmaJet
The first jet injector that is FDA approved for delivery of an influenza vaccine. AFLURIA® Influenza Vaccine is FDA Approved for use with PharmaJet’s Needle-Jet injectors.
The device delivers vaccines either intramuscularly or subcutaneously by means of a narrow, precise fluid stream syringe that delivers the medicine or vaccine through the skin. PharmaJet has proven that it expands immunization coverage, eliminates the risk of needle sticks, reduces health care costs and offers a better patient experience. For more information on PharmaJet, please visithttp://www.abopharmaceuticals.com/pharmajet
1.) "Needle-Free" www.pharmajet.com
Jan 27 - ABO Pharmaceuticals Receives Authorized Distributor Status for Stimate
CSL Behring awards ABO Pharmaceuticals Authorized Distributor for Stimate – The first and only high-concentration desmopressin acetate nasal spray that triggers your body’s natural ability to release von Willebrand factor (VWF), so that your blood can clot properly.
Feb 10 - Announcing the Lanuch of ABO's 'Got FLu?' Program
Our 'got flu?' Program eases the stress of the Flu Season by ensuring the availability of influenza vaccine from not one, but all major manufacturers, including afluria®, the Thimerosal-Free Flu Vaccine.
2014-2015 Influenza Vaccine Composition
The vaccine viruses recommended by WHO for the 2014-15 northern hemisphere influenza season are the same as those for the northern hemisphere 2013-14 influenza season and 2014 southern hemisphere season.
The WHO Vaccine Composition Meeting
for the 2014-2015 season was held February 17 -19, 2014 at WHO headquarters in Geneva, Switzerland. On February 20, the Meeting recommended that trivalent vaccines for use in the Northern Hemisphere 2014-15 influenza season contain the following:
- an A/California/7/2009 (H1N1)pdm09-like virus;
- an A/Texas/50/2012 (H3N2)-like virus;
- a B/Massachusetts/2/2012-like virus.
The Meeting also recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and a B/Brisbane/60/2008-like virus.
For more information about these WHO recommendations, see Questions and Answers
Later this month, VRBAC will meet and decide for the United States the composition for the Northern Hemisphere 2014-2015 influenza vaccine.
The WHO Vaccine Composition Meeting for Southern Hemisphere 2014 influenza season vaccines
was held September 23-26, 2013, at WHO headquarters in Geneva, Switzerland. The recommended composition is the same as the composition of 2013-2014 Northern Hemisphere vaccines.
Protection Against 2009 H1N1 To Be Included in 2010-2011 Seasonal Flu Vaccine
A key U.S. Food and Drug Administration Advisory Committee recommended today that protection against the 2009 H1N1 virus, which was first identified last April, be included in the 2010-2011 seasonal influenza vaccine starting this fall. That means that, barring some unforeseen circumstance, this fall, most Americans will be able to return to the traditional routine of having one flu vaccine to protect them against the major circulating flu viruses. As is always the case with seasonal vaccine, younger children who have never had a seasonal vaccine will still need two doses.
CDC's Advisory Committee on Immunization Practices (ACIP) Recommends Universal Annual Influenza Vaccination
A panel of immunization experts voted today (February 24, 2010) to expand the recommendation for annual influenza vaccination to include all people aged 6 months and older. The expanded recommendation is to take effect in the 2010 - 2011 influenza season. The new recommendation seeks to remove barriers to influenza immunization and signals the importance of preventing influenza across the entire population.
FDA Approves A High Dose Seasonal Influenza Vaccine Specifically Intended for People Ages 65 and Older
The U.S. Food and Drug Administration today approved Fluzone High-Dose, an inactivated influenza virus vaccine for people ages 65 years and older to prevent disease caused by influenza virus subtypes A and B.
bioCSL & Co., Inc. Obtains Exclusive U.S. Marketing Rights for AFLURIA®, Seasonal Influenza Vaccine from CSL Biotherapies
WHITEHOUSE STATION, NJ - bioCSL & Co., Inc. announced today that the Company has entered into an exclusive agreement with CSL Biotherapies, a subsidiary of CSL Limited, to market and distribute AFLURIA® (Influenza Virus Vaccine), CSL's seasonal influenza (flu) vaccine, in the U.S., for the 2010/2011-2015/2016 flu seasons. CSL and bioCSL have been partners in vaccine development and marketing since 1980.
Importance of Influenza Vaccination for Health Care Personnel
With the annual influenza season underway, the Food and Drug Administration (FDA) is urging health care organizations to ensure that influenza vaccination programs are available for health care personnel (HCP).
2009 H1N1 and Pregnancy
This document provides updated information on pregnancy as a risk factor for serious 2009 H1N1-related complications based on findings from a recent study.